Gene expression data helps to improve diagnostics, therapeutic approach
Categories |
Oncology software, cancer diagnosis, personalized medicine |
Development Stage |
Working prototype |
Patent Status |
U.S. patent application filed |
Market Size |
World DNA microarray markets generated revenues worth $596 million in 2003, likely to reach $937 million by 2010 |
Highlights
-
Current cancer diagnosis methods rely on descriptive histopathological data.
-
New technology measures patient microarray data against detailed classification of cancer types from database of extracted and analyzed data and tumor gene expression profiles
-
The method monitors genetic changes enabling improved accuracy of diagnosis
-
Since molecular changes often precede morphological changes, genetic assessment of cancer patients may be used for early detection of the disease.
Our Innovation
-
This new tool measures the similarity between gene expression data derived from DNA microarray tests of a patients malignant tissue with sets of gene expression data from pre-classified malignancies. This graphic presentation of the results forms the genetic signature of the patient and is a powerful and sensitive diagnostic tool.
Key Features
-
Increased diagnostic and detection accuracy
-
Enables cancer diagnosis, prediction of clinical outcomes and formulation of therapeutic approach
-
General method may be used for any type of disease if an adequate size sample of microarrays from previously classified disease is available
Development Milestones
-
Seeking industry cooperation for further development with companies that can prepare datasets
The Opportunity
-
25 million people in Japan, Europe and North America have cancer; 10.1 million additional cases diagnosed worldwide each year. By 2020, that number will grow to 15 million new cases annually. (World Health Organization)
-
New diagnostic techniques such as molecular assays, tissue assays and pharmacodiagnostics had sales of $11 million in 2004, forecasts to reach $480 million by 2009. (Kalorama)